^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH1 mutation + Chr del(1p) + Chr del(19q)

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
    Entrez ID:
    3417
    Related biomarkers:
    Expression
    Mutation
    Others
    12d
    Comprehensive Evaluation of Copy Number Variation from Gene to Arm-Level Using Targeted Sequencing (AMP 2024)
    OCA Plus supports comprehensive detection of relevant copy number alterations in cancer FFPE samples. Combined with small variant profiling, detection of MSI, TMB, and HRD, OCA Plus facilitates comprehensive analysis of DNA structural changes in cancer that are relevant to precision oncology research.
    Tumor mutational burden • BRCA Biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • HRD (Homologous Recombination Deficiency)
    |
    IDH1 mutation • HRD • IDH1 mutation + Chr del(1p) + Chr del(19q)
    |
    Oncomine™ Comprehensive Assay Plus
    1year
    Clinical characteristics and prognostic factors of solitary and multiple adult gliomas: a retrospective study based on propensity score matching. (PubMed, Eur Rev Med Pharmacol Sci)
    The prognosis for multiple gliomas is extremely poor, which is related to the fact that the most common pathological types are glioblastomas and the surgical procedure is challenging. Concurrent chemotherapy and radiotherapy are the strongest protective prognostic factors, and the differences in their molecular pathology expression compared to solitary gliomas remain for further investigation.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NF1 (Neurofibromin 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    TP53 mutation • IDH1 mutation • NF1 mutation • MGMT promoter methylation • IDH1 mutation + Chr del(1p) + Chr del(19q) • TP53 expression
    over1year
    Diffuse leptomeningeal glioneuronal tumor in a child masquerading as an intramedullary spinal pilocytic astrocytoma. (PubMed, Neurooncol Adv)
    Despite the morphologic similarities to pilocytic astrocytoma and the lack of oligodendroglial/neuronal components or leptomeningeal dissemination, the molecular profile was definitive in classifying the tumor as DLGNT. This case highlights the importance of molecular and genetic testing in the characterization of pediatric central nervous system tumors.
    Journal
    |
    BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • KIAA1549
    |
    BRAF mutation • IDH1 mutation • IDH1 mutation + Chr del(1p) + Chr del(19q) • KIAA1549-BRAF fusion • BRAF fusion
    over2years
    Identifying Differential Expression Genes and Prognostic Signature Based on Subventricular Zone Involved Glioblastoma. (PubMed, Front Genet)
    Here, a novel gene signature based on DEGs between GBM and healthy SVZ was developed for determining GBM patient prognosis. Targeting these genes may be a therapeutic strategy for GBM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • BCAT1 (Branched Chain Amino Acid Transaminase 1 ) • NNMT (Nicotinamide N-Methyltransferase) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    |
    PD-L1 expression • IDH1 mutation • IDH1 mutation + Chr del(1p) + Chr del(19q)